Answers are grounded in this paper and cite their sources.
Observational analysis suggests anti-CGRP therapy improves long-term outcomes in medication-overuse headache, highlighting the need for patient education.
Anti-CGRP antibodies offer a targeted strategy capable of interrupting the cycle of overuse and sensitization underlying MOH. Early initiation of anti-CGRP therapy during ongoing overuse appears effective and well tolerated, but long-term outcomes are likely improved when treatment is accompanied by patient education and, in selected cases, structured withdrawal.
No takes yet. Share an insight, caveat, or question.
Pellesi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: